Trials / Active Not Recruiting
Active Not RecruitingNCT03264664
Study of E7386 in Participants With Selected Advanced Neoplasms
An Open-Label, Multicenter, Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7386 | Oral immediate release tablets. |
Timeline
- Start date
- 2017-07-27
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2017-08-29
- Last updated
- 2026-03-06
Locations
10 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT03264664. Inclusion in this directory is not an endorsement.